For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
CCTG is happy to announce the launch of the new Investigator Leadership Mentoring and Training (VISION) program. As part of our mandate to support training and education within the network, this program aims to provide CCTG investigators the opportunity to enhance their leadership skills through interactive, expert-facilitated workshops.
Congratulations to Dr. Simron Singh who was named as Chair in Neuroendocrine Medical and Systemic Cancer Care & Research, jointly shared by Sunnybrook Health Sciences Centre and the University of Toronto’s Temerty Faculty of Medicine. As Chair he will support a combination of clinical trial innovation, precision biomarker discovery, and translational research integration at Sunnybrook.
The 2026 ASCO Gastrointestinal Cancer Symposium was held on January 8-10, 2026 in San Francisco, California see all the CCTG Abstracts below.
The results of the BR.31 global Phase III study, testing adjuvant durvalumab in patients with completely resected non–small cell lung cancer (NSCLC) and led by Canadian Cancer Trials Group (CCTG), were published in the Journal of Clinical Oncology.
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable).
Please join us in welcoming Darren Frew who will be supporting the CCTG Gastrointestinal disease site committee. He resides in Burnaby BC and was treated successfully for colon cancer via surgery and chemotherapy in 2019/ 2020. He is grateful the treatment went well and continues in the right direction.
The CO.21 CHALLENGE trial has been selected by the editors as one of the top NEJM 15 articles of 2025.
